DAPT Score Overview
The DAPT (Dual Antiplatelet Therapy) score is an essential clinical decision-making tool designed to help cardiologists determine the optimal duration of dual antiplatelet therapy—typically a combination of aspirin and a P2Y12 inhibitor (like clopidogrel, prasugrel, or ticagrelor)—beyond the standard 12 months following a percutaneous coronary intervention (PCI) with stent placement.
Balancing Ischemic and Bleeding Risks
The core challenge in post-stent management is balancing two competing risks:
- Ischemic Risk: The danger of a blood clot forming inside the stent (stent thrombosis) or experiencing another myocardial infarction. This risk favors longer DAPT.
- Bleeding Risk: The danger of major, potentially life-threatening hemorrhage caused by prolonged use of potent blood thinners. This risk favors shorter DAPT.
Interpreting the Score
The score assigns positive points to factors that increase ischemic risk (like prior MI, vein graft stents, or diabetes) and negative points to factors that increase bleeding risk (like older age).
- Score < 2: Standard DAPT (typically 12 months) is favored because the risk of major bleeding outweighs the anticipated ischemic benefit of continuing therapy.
- Score >= 2: Prolonged DAPT (up to 30 months) is favored because the reduction in ischemic events and stent thrombosis outweighs the increased risk of bleeding.
Score = Age Points + Ischemic Factors - Bleeding Factors